IP Library Granted Patent US 9,173,906
Granted Patent B2
US 9,173,906 · App. 14/176,954 · Granted Nov 3, 2015

Methods and compositions for tissue regeneration

Inventors: Eric Rolland (Divonne les bains, FR); Thomas Hunziker (Oberhofen, CH); Beatrice Chevallay (Lugrin, FR); Christopher Rinsch (Morges, CH)
Assignee: Smith & Nephew, Inc.
A61K35/36A61K9/0014A61K9/10A61K9/19A61K35/33A61K38/18A61K38/19A61K38/363A61K38/4833A61K41/0023A61K47/10A61L15/40A61L26/0057A61L27/3616A61L27/3633A61L27/3804A61L27/3813A61L27/3886C12N5/0656C12N5/0698A61K48/00C12N2502/094C12N2502/1323C12N2510/00C12N2510/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,173,906
App. No.
14/176,954
Granted
Nov 3, 2015
Kind
B2
Abstract

A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vile, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, TGFα, and TNFα, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second vial.

Claims (20)

1. A composition comprising mitotically inactive autologous or allogeneic cells that are capable of secreting one or more biologically active molecules selected from GM-CSF, VEGF, KGF, aFGF, bFGF, TGFβ, angiopoietin, EGF, IL-1β, IL-6, IL-8, PDGF, HGF/SF, IGF-1, CSF-1, TGFα, and TNFα, wherein the composition is comprised in a buffered solution, a wound dressing, or an extracellular matrix or matrix material.

2. The composition of claim 1 , wherein the cells are allogeneic.

3. The composition of claim 1 wherein the cells are mitotically inactivated by irradiation.

4. The composition of claim 3 , wherein the cells are mitotically inactivated by irradiation with gamma rays, X-rays, or UV light.

5. The composition of claim 1 , wherein the cells are mitotically inactivated by administration of chemically-based mitotic inhibitors.

6. The composition of claim 1 , wherein the cells are differentiated.

7. The composition of claim 1 , wherein the concentration of cells are in the range of about 1×10 3 cells/μl to about 50×10 3 cells/μl.

8. The composition of claim 1 , wherein the composition is comprised in a buffered solution.

9. The composition of claim 8 , wherein the buffered solution is HBSS.

10. The composition of claim 9 , wherein the HBSS comprises Ca++ and Mg++.

11. The composition of claim 1 , wherein the cell preparation is comprised in a wound dressing.

12. The composition of claim 1 , wherein the composition is comprised in an extracellular matrix or matrix material.

13. The composition of claim 1 , wherein the composition is in the form of a paste.

14. The composition of claim 1 , wherein the composition is in the form of a spray.

15. The composition of claim 1 , further comprising a cryoprotectant.

16. The composition of claim 15 , wherein the composition is cryopreserved.

17. The composition of claim 1 , wherein the composition is comprised in a container.

18. The composition of claim 1 , wherein the composition is comprised in a sterile vial.

19. A method of administering the composition of claim 1 to a wound, the method comprising administering the composition to the wound.

20. A method of storing the composition of claim 1 , the method comprising placing the composition in a container and storing the composition.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: ROLLAND, ERIC; HUNZIKER, THOMAS; CHEVALLAY, BEATRICE; RINSCH, CHRISTOPHER
To: ISOTIS SA
Reel/Frame 036224/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: ISOTIS SA
To: EPISOURSE SA
Reel/Frame 036224/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: EPISOURSE SA
To: DFB PHARMACEUTICALS, INC.
Reel/Frame 036224/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: DFB PHARMACEUTICALS, INC.
To: DFB TECHNOLOGY HOLDINGS, LLC
Reel/Frame 036224/0950 →
CHANGE OF NAME Recorded Jul 31, 2015
From: HEALTHPOINT HOLDINGS, LLC; DFB TECHNOLOGY HOLDINGS, LLC
To: HEALTHPOINT INTERNATIONAL, LLC
Reel/Frame 036225/0426 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: HEALTHPOINT INTERNATIONAL, LLC
To: SMITH & NEPHEW, INC.
Reel/Frame 036225/0567 →
Continuity (9)
Continuation 13659378 · Oct 24, 2012
Continuation 13368706 · Feb 8, 2012
Continuation 12967619 · Dec 14, 2010
Continuation 12562767 · Sep 18, 2009
Continuation 12255481 · Oct 21, 2008
Continuation 10526853
Continuation 10324257 · Dec 19, 2002
Provisional Application 60408565 · Sep 6, 2002
Related Publication 20140377229A1 · Dec 25, 2014